Shiroma Donna
Known title: General CounselCIK: 0001816251
Associated companies
Transaction History
| RCEL | ▲ Buy | Grant | 2,225 | $18K | 5/31/2024 | View on chart |
| RCEL | ▲ Buy | Grant | 1,469 | $13K | 11/30/2023 | View on chart |
| RCEL | ▼ Sell | Open Market | 4,193 | $66K | 8/21/2023 | View on chart |
| RCEL | ▲ Buy | Grant | 35,950 | — | 7/1/2022 | View on chart |
| RCEL | ▲ Buy | Grant | 10,500 | — | 7/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat
PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.